Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

THE FDA HAS APPROVED ABBVIE'S RINVOQ (UPADACITINIB) FOR THE TREATMENT OF GIANT CELL ARTERITIS, MAKING IT THE NINTH APPROVED INDICATION FOR THE DRUG. THIS ALSO MARKS THE FIRST TIME AN ORAL JAK INHIBITOR HAS BEEN APPROVED FOR THIS PREVALENT FORM OF VASCULITIS IN WESTERN COUNTRIES. RINVOQ'S APPROVAL HAS SPARKED COMPETITION AMONG OTHER PHARMACEUTICAL COMPANIES IN THE GIANT CELL ARTERITIS MARKET. THE FDA HAS APPROVED ABBVIE'S RINVOQ (UPADACITINIB) FOR THE TREATMENT OF GIANT CELL ARTERITIS, MAKING IT THE NINTH APPROVED INDICATION FOR THE DRUG. THIS ALSO MARKS THE FIRST TIME AN ORAL JAK INHIBITOR HAS BEEN APPROVED FOR THIS PREVALENT FORM OF VASCULITIS IN WESTERN COUNTRIES. RINVOQ'S APPROVAL HAS SPARKED COMPETITION AMONG OTHER PHARMACEUTICAL COMPANIES IN THE GIANT CELL ARTERITIS MARKET.

GIANT-CELL ARTERITIS MARKET HEATS UP WITH ABBVIE'S RINVOQ APPROVAL | DELVEINSIGHT

WATERTOWN, MASS.--(BUSINESS WIRE)--ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO CREATING SMALL MOLECULE DRUGS FOR VIRAL INFECTIONS AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED A LABEL EXPANSION FOR MAVYRET (GLECAPREVIR/PIBRENTASVIR), AN ORAL PANGENOTYPIC DIRECT ACTING ANTIVIRAL (DAA) THERAPY. IT IS NOW APPROVED AS THE ONLY EIGHT-WEEK TREATMENT FOR ADULTS AND PEDIATRIC PATIENTS THREE.

ENANTA PHARMACEUTICALS' PARTNER ABBVIE RECEIVES U.S. FDA APPROVAL OF AN EXPANDED INDICATION FOR MAVYRET (GLECAPREVIR/PIBRENTASVIR) AS THE FIRST AND ONLY TREATMENT FOR PEOPLE WITH ACUTE HEPATITIS C VIRUS

MAVYRET (GLECAPREVIR/PIBRENTASVIR) IS THE FIRST AND ONLY ORAL EIGHT-WEEK PANGENOTYPIC TREATMENT OPTION APPROVED FOR PEOPLE WITH ACUTE OR CHRONIC HEPATITIS C VIRUS (HCV)* WITH THIS APPROVAL, PROVIDERS CAN NOW TREAT HCV PATIENTS IMMEDIATELY AT THE TIME OF DIAGNOSIS HCV IS A CURABLE CONDITION, BUT PATIENTS CAN OFTEN GO UNDIAGNOSED.1 IF LEFT UNTREATED, PEOPLE WITH ACUTE HCV COULD PROGRESS TO CHRONIC DISEASE, INCLUDING LIVER-RELATED COMPLICATIONS, SUCH AS CIRRHOSIS OR LIVER CANCER1 THE APPROVAL SUPPORTS GLOBAL CLINICAL GUIDELINES TO ADVANCE TESTING AND TREATMENT FOR PEOPLE WITH HCV REGARDLESS OF CHRONICITY, AND SUPPORTS PUBLIC HEALTH GOALS FOR DISEASE ELIMINATION NORTH CHICAGO, ILL. , JUNE 11, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVED A LABEL EXPANSION FOR MAVYRET (GLECAPREVIR/PIBRENTASVIR), AN ORAL PANGENOTYPIC DIRECT ACTING ANTIVIRAL (DAA) THERAPY.

U.S. FDA APPROVES EXPANDED INDICATION FOR ABBVIE'S MAVYRET (GLECAPREVIR/PIBRENTASVIR) AS FIRST AND ONLY TREATMENT FOR PEOPLE WITH ACUTE HEPATITIS C VIRUS

THE ABBVIE MIGRAINE CAREER CATALYST AWARD CONTEST IS NOW OPEN FOR ENTRIES, OFFERING FINANCIAL SUPPORT TO HELP WINNERS PURSUE CAREER AND PROFESSIONAL DEVELOPMENT GOALS. AS THE ONLY COMPANY WITH THREE APPROVED PRODUCTS DESIGNED TO MEET PATIENT NEEDS ACROSS THE SPECTRUM OF MIGRAINE, ABBVIE IS COMMITTED TO SUPPORTING THE MIGRAINE COMMUNITY BEYOND TREATMENT.

ABBVIE INVITES PEOPLE LIVING WITH MIGRAINE TO ENTER THE SECOND ANNUAL ABBVIE MIGRAINE CAREER CATALYST AWARD CONTEST TO SUPPORT THEIR PROFESSIONAL GOALS

NORTH CHICAGO, ILL. , JUNE 3, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) WILL PARTICIPATE IN THE GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE ON TUESDAY, JUNE 10, 2025.

ABBVIE TO PRESENT AT THE GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

CHICAGO-BASED INSTITUTIONS AIM TO CREATE GREATER AWARENESS FOR CANCER ADVOCACY AND TO SUPPORT NON-PROFIT CANCER ORGANIZATIONS NORTH CHICAGO, ILL. , MAY 30, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) ANNOUNCED A MULTI-YEAR PARTNERSHIP WITH THE CHICAGO CUBS TO SUPPORT PEOPLE LIVING WITH CANCER THROUGH A CAMPAIGN CALLED "STRIKING OUT CANCER" WHICH STARTS TODAY WHEN THE CHICAGO CUBS PLAY THE CINCINNATI REDS.

ABBVIE PARTNERS WITH CHICAGO CUBS ON "STRIKING OUT CANCER"

-  KEY ORAL PRESENTATIONS HIGHLIGHT NEW DATA FROM ABBVIE'S NOVEL INVESTIGATIONAL ANTIBODY-DRUG CONJUGATES (ADCS) INCLUDING TELISOTUZUMAB ADIZUTECAN (ABBV-400, TEMAB-A) IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC), ABBV-706 IN HIGH-GRADE NEUROENDOCRINE NEOPLASMS (NENS) AND PIVEKIMAB SUNIRINE (PVEK) IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN). NORTH CHICAGO, ILL.

ABBVIE FEATURES NEW DATA ACROSS DIFFICULT-TO-TREAT SOLID TUMORS AND BLOOD CANCERS AT ASCO 2025, HIGHLIGHTING BREADTH AND DEPTH OF ITS ONCOLOGY PORTFOLIO

NEW YORK , MAY 22, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OFCEREVEL THERAPEUTICS HOLDINGS, INC. (NYSE: ABBV). SHAREHOLDERS WHO PURCHASED SHARES OF ABBV DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENT.

CEREVEL THERAPEUTICS HOLDINGS, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE GROSS LAW FIRM BEFORE JUNE 3, 2025 TO DISCUSS YOUR RIGHTS - ABBV

NEW YORK, MAY 21, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF CEREVEL THERAPEUTICS HOLDINGS, INC. (NYSE: ABBV).

CEREVEL THERAPEUTICS HOLDINGS, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE GROSS LAW FIRM BEFORE JUNE 3, 2025 TO DISCUSS YOUR RIGHTS  ABBV

 EMRELIS IS THE FIRST AND ONLY TREATMENT APPROVED FOR PREVIOUSLY TREATED ADVANCED NSCLC PATIENTS WITH HIGH C-MET PROTEIN OVEREXPRESSION WHO OFTEN FACE POOR PROGNOSIS AND HAVE LIMITED TREATMENT OPTIONS  LUNG CANCER REMAINS THE LEADING CAUSE OF CANCER-RELATED DEATHS THROUGHOUT THE WORL D1 NORTH CHICAGO, ILL. , MAY 14, 2025 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT EMRELIS (TELISOTUZUMAB VEDOTIN-TLLV) HAS BEEN GRANTED ACCELERATED APPROVAL BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC, NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) WITH HIGH C-MET PROTEIN OVEREXPRESSION (OE) WHO HAVE RECEIVED A PRIOR SYSTEMIC THERAPY.

U.S. FDA APPROVES EMRELIS (TELISOTUZUMAB VEDOTIN-TLLV) FOR ADULTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH HIGH C-MET PROTEIN OVEREXPRESSION

- COLLABORATION TO LEVERAGE ABBVIE'S EXPERTISE IN BIOTHERAPEUTIC DRUG DEVELOPMENT AND COMMERCIALIZATION TOGETHER WITH ADARX'S PROPRIETARY RNA TECHNOLOGY TO ADVANCE NEXT-GENERATION SIRNA THERAPIES ACROSS NEUROSCIENCE, IMMUNOLOGY AND ONCOLOGY NORTH CHICAGO, ILL. AND SAN DIEGO , MAY 14, 2025 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) AND ADARX PHARMACEUTICALS, A LATE CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NEXT-GENERATION RNA THERAPEUTICS, TODAY ANNOUNCED A COLLABORATION AND LICENSE OPTION AGREEMENT TO DEVELOP SMALL INTERFERING RNA (SIRNA) THERAPEUTICS ACROSS MULTIPLE DISEASE AREAS, INCLUDING NEUROSCIENCE, IMMUNOLOGY AND ONCOLOGY.

ABBVIE AND ADARX PHARMACEUTICALS ANNOUNCE COLLABORATION AND LICENSE OPTION AGREEMENT TO DEVELOP NEXT-GENERATION SIRNA THERAPIES ACROSS MULTIPLE THERAPEUTIC AREAS

OXFORD, ENGLAND--(BUSINESS WIRE)-- #BIOTECH--ETCEMBLY HAS SIGNED A COLLABORATION AGREEMENT WITH DJS ANTIBODIES, A PART OF ABBVIE, TO ACCELERATE THE DISCOVERY OF NOVEL ANTIBODY THERAPEUTICS.

TECHBIO PIONEER ETCEMBLY SIGNS DEAL WITH DJS ANTIBODIES, PART OF ABBVIE, TO ACCELERATE ANTIBODY DISCOVERY PIPELINE

NEW YORK, MAY 12, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF CEREVEL THERAPEUTICS HOLDINGS, INC. (NYSE: ABBV).

NORTH CHICAGO, ILL. , MAY 6, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) WILL PARTICIPATE IN THE BANK OF AMERICA SECURITIES HEALTHCARE CONFERENCE ON WEDNESDAY, MAY 14, 2025.

ABBVIE TO PRESENT AT THE BANK OF AMERICA SECURITIES HEALTHCARE CONFERENCE

NEW YORK, MAY 05, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN CEREVEL THERAPEUTICS HOLDINGS, INC. ("CEREVEL THERAPEUTICS HOLDINGS, INC." OR THE "COMPANY") (NYSE: ABBV) OF A CLASS ACTION SECURITIES LAWSUIT.

CEREVEL THERAPEUTICS HOLDINGS, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT LEVI & KORSINSKY BEFORE JUNE 3, 2025 TO DISCUSS YOUR RIGHTS  ABBV

NEW YORK , MAY 2, 2025 /PRNEWSWIRE/ -- LEVI &KORSINSKY, LLP NOTIFIES INVESTORS IN CEREVEL THERAPEUTICS HOLDINGS, INC. ("CEREVEL THERAPEUTICS HOLDINGS, INC." OR THE "COMPANY") (NYSE: ABBV) OF A CLASS ACTION SECURITIES LAWSUIT. CLASS DEFINITION: THE LAWSUIT SEEKS TO RECOVER LOSSES ON BEHALF OF CEREVEL THERAPEUTICS HOLDINGS, INC. INVESTORS WHO WERE ADVERSELY AFFECTED BY ALLEGED SECURITIES FRAUD.

SHAREHOLDERS OF CEREVEL THERAPEUTICS HOLDINGS, INC. SHOULD CONTACT LEVI & KORSINSKY BEFORE JUNE 3, 2025 TO DISCUSS YOUR RIGHTS - ABBV

BOTOX COSMETIC WILL PROVIDE 250 ENTREPRENEURS WITH ACCESS TO NEW RESOURCES AND OPPORTUNITIES AND WILL AWARD 20 GRANTS WORTH $20,000 EACH TO SUPPORT BUSINESS GOALS. BY 2030, BOTOX COSMETIC PLEDGES TO EMPOWER 50,000 ENTREPRENEURS, HELPING TO CLOSE THE CONFIDENCE GAP.

BOTOX COSMETIC (ONABOTULINUMTOXINA) CONTINUES ITS MISSION OF EMPOWERING ENTREPRENEURS THROUGH "THE CONFIDENCE PROJECT"

 RINVOQ (UPADACITINIB) IS NOW THE FIRST AND ONLY ORAL JANUS KINASE (JAK) INHIBITOR APPROVED FOR THE TREATMENT OF GCA IN ADULTS  ALSO KNOWN AS TEMPORAL ARTERITIS, GCA IS THE MOST COMMON VASCULITIS AFFECTING ADULTS IN WESTERN COUNTRIES 2  THIS MARKS THE NINTH APPROVED INDICATION FOR RINVOQ IN THE U.S., ACROSS RHEUMATOLOGY, GASTROENTEROLOGY, AND DERMATOLOGY1 NORTH CHICAGO, ILL. , APRIL 29, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED RINVOQ (UPADACITINIB), 15 MG, ONCE DAILY,FOR THE TREATMENT OF ADULTS WITH GIANT CELL ARTERITIS (GCA).1 THIS COMES AFTER THE EUROPEAN COMMISSION RECENTLY GRANTED MARKETING AUTHORIZATION OF RINVOQ FOR THE TREATMENT OF GCA IN ADULT PATIENTS.

RINVOQ (UPADACITINIB) RECEIVES U.S. FDA APPROVAL FOR GIANT CELL ARTERITIS (GCA)

NEW YORK , APRIL 28, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OFCEREVEL THERAPEUTICS HOLDINGS, INC. (NYSE: ABBV). SHAREHOLDERS WHO PURCHASED SHARES OF ABBV DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENT.

SHAREHOLDERS OF CEREVEL THERAPEUTICS HOLDINGS, INC. SHOULD CONTACT THE GROSS LAW FIRM BEFORE JUNE 3, 2025 TO DISCUSS YOUR RIGHTS - ABBV

REPORTS FIRST-QUARTER DILUTED EPS OF $0.72 ON A GAAP BASIS, A DECREASE OF 6.5 PERCENT; ADJUSTED DILUTED EPS OF $2.46, AN INCREASE OF 6.5 PERCENT; THESE RESULTS INCLUDE AN UNFAVORABLE IMPACT OF $0.13 PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE DELIVERS FIRST-QUARTER NET REVENUES OF $13.343 BILLION, AN INCREASE OF 8.4 PERCENT ON A REPORTED BASIS OR 9.8 PERCENT ON AN OPERATIONAL BASIS FIRST -QUARTER GLOBAL NET REVENUES FROM THE IMMUNOLOGY PORTFOLIO WERE $6.264 BILLION, AN INCREASE OF 16.6 PERCENT ON A REPORTED BASIS, OR 18.1 PERCENT ON AN OPERATIONAL BASIS; GLOBAL SKYRIZI NET REVENUES WERE $3.425 BILLION; GLOBAL RINVOQ NET REVENUES WERE $1.718 BILLION; GLOBAL HUMIRA NET REVENUES WERE $1.121 BILLION  FIRST-QUARTER GLOBAL NET REVENUES FROM THE NEUROSCIENCE PORTFOLIO WERE $2.282 BILLION, AN INCREASE OF 16.1 PERCENT ON A REPORTED BASIS, OR 17.0 PERCENT ON AN OPERATIONAL BASIS; GLOBAL VRAYLAR NET REVENUES WERE $765 MILLION; GLOBAL BOTOX THERAPEUTIC NET REVENUES WERE $866 MILLION; COMBINED GLOBAL UBRELVY AND QULIPTA NET REVENUES WERE $433 MILLION  FIRST-QUARTER GLOBAL NET REVENUES FROM THE ONCOLOGY PORTFOLIO WERE $1.633 BILLION, AN INCREASE OF 5.8 PERCENT ON A REPORTED BASIS, OR 7.5 PERCENT ON AN OPERATIONAL BASIS; GLOBAL IMBRUVICA NET REVENUES WERE $738 MILLION; GLOBAL VENCLEXTA NET REVENUES WERE $665 MILLION; GLOBAL ELAHERE NET REVENUES WERE $179 MILLION  FIRST -QUARTER GLOBAL NET REVENUES FROM THE AESTHETICS PORTFOLIO WERE $1.102 BILLION, A DECREASE OF 11.7 PERCENT ON A REPORTED BASIS, OR 10.2 PERCENT ON AN OPERATIONAL BASIS; GLOBAL BOTOX COSMETIC NET REVENUES WERE $556 MILLION; GLOBAL JUVEDERM NET REVENUES WERE $231 MILLION  RAISES 2025 ADJUSTED DILUTED EPS GUIDANCE RANGE FROM $11.99 - $12.19 TO $12.09 - $12.29, WHICH INCLUDES AN UNFAVORABLE IMPACT OF $0.13 PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE INCURRED YEAR-TO-DATE THROUGH THE FIRST QUARTER 2025 NORTH CHICAGO, ILL. , APRIL 25, 2025 /PRNEWSWIRE/ --ABBVIE (NYSE:ABBV) ANNOUNCED FINANCIAL

ABBVIE REPORTS FIRST-QUARTER 2025 FINANCIAL RESULTS

NEW YORK, NY / ACCESS NEWSWIRE / APRIL 24, 2025 / IF YOU SUFFERED A LOSS ON YOUR CEREVEL THERAPEUTICS HOLDINGS, INC. (NYSE:ABBV) INVESTMENT AND WANT TO LEARN ABOUT A POTENTIAL RECOVERY UNDER THE FEDERAL SECURITIES LAWS, FOLLOW THE LINK BELOW FOR MORE INFORMATION: HTTPS://ZLK.COM/PSLRA-1/CEREVEL-THERAPEUTICS-HOLDINGS-INC-LAWSUIT-SUBMISSION-FORM?PRID=144878&WIRE=1 OR CONTACT JOSEPH E. LEVI, ESQ.

CEREVEL THERAPEUTICS HOLDINGS, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT LEVI & KORSINSKY BEFORE JUNE 3, 2025 TO DISCUSS YOUR RIGHTS - ABBV

TRENIBOTE IS A FIRST-IN-CLASS BOTULINUM NEUROTOXIN SEROTYPE E CHARACTERIZED BY A RAPID ONSET OF ACTION AS EARLY AS 8 HOURS AFTER ADMINISTRATION (EARLIEST ASSESSMENT TIME) AND SHORTER DURATION OF EFFECT OF 2-3 WEEKS.  IF APPROVED, TRENIBOTE WILL BE THE FIRST NEUROTOXIN OF ITS KIND AVAILABLE TO PATIENTS.

ABBVIE SUBMITS BIOLOGICS LICENSE APPLICATION TO U.S. FDA FOR TRENIBOTULINUMTOXINE (TRENIBOTE) FOR THE TREATMENT OF GLABELLAR LINES

NEW YORK, APRIL 23, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF CEREVEL THERAPEUTICS HOLDINGS, INC. (NYSE: ABBV).

CEREVEL THERAPEUTICS HOLDINGS, INC. SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT THE GROSS LAW FIRM BEFORE JUNE 3, 2025 TO DISCUSS YOUR RIGHTS  ABBV

NEW YORK, NY / ACCESS NEWSWIRE / APRIL 11, 2025 / IF YOU SUFFERED A LOSS ON YOUR CEREVEL THERAPEUTICS HOLDINGS, INC. (NYSE:ABBV) INVESTMENT AND WANT TO LEARN ABOUT A POTENTIAL RECOVERY UNDER THE FEDERAL SECURITIES LAWS, FOLLOW THE LINK BELOW FOR MORE INFORMATION: HTTPS://ZLK.COM/PSLRA-1/CEREVEL-THERAPEUTICS-HOLDINGS-INC-LAWSUIT-SUBMISSION-FORM?PRID=142536&WIRE=1 OR CONTACT JOSEPH E. LEVI, ESQ.

AbbVie Inc.

ABBV

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Press Releases

AbbVie Inc.

ABBV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Press Releases

ABBV